In the Asian medical device market, although PVC is still a very commonly used material, However, considering the environmental issues during routine use and disposal, and the safety risks to infants or pregnant women are particularly prominent, medical devices containing PVC are being phased out. As a safe, stable and high-quality alternative material, thermoplastic polyurethane (TPU) is gradually becoming the preferred material in the biomedical field due to its good biocompatibility and stability, high strength, low friction coefficient and good flexibility. . Especially for medical devices introduced into the human body, in the field of implantable medical devices with excellent biological stability and compatibility and high mechanical strength requirements, TPU elastomer is the best choice.
TPUApplications in the field of medical consumables are concentrated in some high value-added industries, such as artificial heart assist devices, medical catheters, medical films, and medical artificial leather. Most of TPU’s application products in the medical industry are mid-to-high-end products, which have high requirements for product safety, performance, consistency, etc. When purchasing such products downstream, the price is often not the most important thing, and the quality of the product is the first consideration. Therefore, large foreign-funded manufacturers like Lubrizol are very competitive in the market, and multinational companies such as Lubrizol, Covestro, and BASF occupy a dominant position in the field of medical TPU.
TPU It has very great application prospects in the medical field, but due to the limitation of high cost, the current application proportion in the medical industry is still very low. From 2018 to 2022, China’s demand for TPU in the medical field will grow at a five-year compound growth rate of 18.9%, which has been in a high-speed growth stage for a long time. In 2022, China’s TPU demand in the medical industry will reach 6,100 tons, a year-on-year decrease of 12.9%. The reason for the obvious decline in growth in 2022 is mainly due to the postponement of procurement due to a large number of hospital visits and surgical treatment delays caused by epidemic control.
my country’s medical TPU is currently in its infancy, and enterprises with R & D advantages are expected to complete Localized substitution, there is still a broad market space in the future.
微信扫一扫打赏
